The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2020 | Therapy strategies for accelerated and blastic phase MPN
Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the importance of montioring patients who show signs and symptoms of myeloproliferative neoplasms (MPNs), and that early interventions followed by transplantation is important. To prevent further progression, hypomethylating agents are now used in combination with JAK inhibitors, such as ruxolitinib, to help get patients to transplantation. Around 20–25% of patients that have transformations have mutations in IDH for which treatments are commercially available and can help achieve meaningful responses, and take patients to transplantation. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
